T he flow-Through Method (USP Apparatus 4), designed to test the dissolution characteristics of a wide range of dosage fonTIS, is becoming incrensingly popular alllong the pharmaceutical hi erarchy. It has been incorporated into severa l internati onal pharl11~lcopoeias.
Using commercially available equjpment, interlaboratory reproducibility of USP Apparatus 4 systems has been shown to be comparable to the USP paddle method (Apparatus 2) in many cases.
General
When tested in cl,e Row-through cell , a specimen is placed in a sma ll testing chamber with a vo lume of about 20 mL (which is maint;1ined at +37°C), and rcle:.lSe is studied tmder continuous flow conditions. From a reservoir, the medium is pumped across a heat exdlanger for tcmper:Julre control and enters the cells from the bottom. The flow rate of the SOTAX piston pump, for examp le, is adjustable up to 50mUmin. while pump rates of8-32 InUmjJ1. ha ve become the standard flow range. The solvent flows upward through the cel l and a filter system which removes undissolved particles.
Why Apparatus 41
Apparatus 4 is well-suited to the determination of the dissolution rate of not only tablets and coated tablets, but also to suppositories, soft gelatin capsules, implants/micro capsu les, powders and granules. It is particularly useful for sustained release products and analyses where pH changes arc desired.
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The fo ll owi ng advantages are recogni zed, particularly in comparison with dlC more conventional stirrer methods (USP Apparatus 1 and 2).
1. There are very few apparatus parameters which affect the test and have to be standardizedj 2. Tdea l hydrodynamic conditions for turbulent and laminar solvent fl ow cond itions existj 3. "'lorking with unlimi ted amou nt of solvent is possible, thus overcoming problems due to nonsink conditions;
4. pH changes may be easil y performed stepwise since medium is exchanged very rapidly in the low volume cells (10-30 mL). (This allows adaptation of test parameters to physiologic conditions.); 5. Apparatus 4 allows for easy positioning and consistent testing of a wide variety of sa mpl e types, including powders, granu les, implants/microcapsules, "floaters", suppositories, and soft gelatin capsu les as well as conventiona l tab lets and coated tablets;
6. Tests ca n be run either in an open or closed system (e.g. fixed or unlimited solvent amount).
Parameter Selection

• Cell Configuration
The dissolution test apparatus' main module typically features assemblies for e ith er 6 or 7 dissolution cells. Before reaching cl,e cells, the so lvent is pumped through heat exchangers which arc placed in an electroni cal ly re6 .... ,Jated thermostatted bath , assuring a test temperanu·e of3 7° ~ O.soC, which is constancly controlled and displayed. The cells may be cl,ennostatted as well. Cell Jo,. SIIpposito,.ies nlld soft gelflt;1I ctlpsllles: This cell is preferably used for suppositories and is designed such that the lipophil ic masses don't block the filters.
Celt for implants/microcapsules: T his ceJl has ~l
vo lum e of o nl y I mL and is preferably used for dissolution testing of implan ts which em last several weeks or even months. The small volume of rl,e cell is required because of the very low Aow rate (e.g. SmLlh r.) for such types of dissolution tests. The re(lllired medium exchange in the cell ca n therefore be assu red. Suitable fine filters prevent the removal of the non-dissolved particles .
• Flow Conditions
Apparatus 4 After passing through the ce ll s, the e1uents are filtered within the filter heads :lIld then either collected or transferred directly to the spectrophotometer for ana lys is. Usua ll y a rou nd filter with a retention ca pacity of 2.7 microns is suitab le since it ca n be complimented with a second filter with a retention capacity of 0.7 micron.
T he Aow rate throughout the cell must be specifi ed individually for each product. USP, for exampl e, recommends a fl ow rate of between 240 and 960 mL/ hour (-l to 16 mL/ min.) 16 mL/ m.in. is frequently used as the sta ndard fl ow rate in pharmaceutical laboratories. T he flow should Ix! mainclined at ± 5% throughout the entire test. T he flow profile must be uniform.
The pump performance has been found to be absol utely critica l to the successful imp lement.1tion of USP Apparanls 4 analyses. SOTAX has developed a pi ston pump especially adopted to ensure t he required Aow profile in Apparanls 4 dissolution rests. It ensu res high performance .l nd superb delivery consistency. T he va lve heads are made of PVDF, assuring::1I1 inert flow path. The Aow rate con be stepless adjusted up Primer ... cont.
to 50mUmin. by means of piston stroke adjustments, and each of the 7 chann els ca n be switched ON or OFF independent of the others. T he movement of the pistons (a t 120 strokes/min.) ensures a dearly defined flow profil e, th us th e Bow rate remains constant, independent of th e fl ow resistan ce imposed, for exa mple, by the filter in the cell head.
• Sampling/Automation Particularl y for sustained release products and for other long term tria ls, manual sampling is not only time consuming but also tedious. Orfline automation is therefore the aim of most laboratories when using the flow-through method.
On-l ine systems may also be confib ru_ red.
[n off-line operati on, the individual sample fraction can be automatica lly coll ected to a fractio n colJ ector, and, after a test rUIl , analysis may be perfonned with a suitable system (e.g. 
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Automated systems are generally interfaced to a PC which controls the bath, the pump and the test procedure, and processes the data. For each test, individual fractions ca n be collected at predetermined interva ls. Multipl e med ia can be pre-se lected in order to provide pH change during the test. In the most sophisticated systems, the test preparation procedure before the test-start and clean-
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ing procedure after the tcst, may also be automated. Batch samplers ma y allow up to six sequentia l sets o f anal yses to be performed compl etely unattended.
The future of Apparatus 4
Dissolu tion analysis using Appararus 4 continues to grow in po pularity. Many pharma ceutical compani es in the United States and throughout the world are currently developing new metllods utilizing Apparatus 4. As sustained release products continue to become increasingly impoTtlnt to tile phanllaceutical community, Appararus 4 uti lization will continue to grow and it5 routine use wiJl be<:ome more widespread.
